We completed a Phase I ALS trial —to demonstrate the safety of the naturally occurring amino acid, L-serine, in humans—that showed encouraging signs of slowing disease progression among enrolled patients.
Read the research here.
We completed a Phase I ALS trial —to demonstrate the safety of the naturally occurring amino acid, L-serine, in humans—that showed encouraging signs of slowing disease progression among enrolled patients.
Read the research here.